Fort Vancouver Investment Management’s TG Therapeutics TGTX Stock Holding History

Fort Vancouver Investment Management’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$550	Buy	+10	New	+$409	﹤0.01%	54

Other funds holding TGTX

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

PCM

Penn Capital Management Philadelphia, Pennsylvania $1.58B AUM 81.2% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

ACM

ACT Capital Management Wayne, Pennsylvania $153M AUM

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Fort Vancouver Investment Management's TGTX Position: Q2 2026 in Review

Fort Vancouver Investment Management opened a new position in TG Therapeutics (TGTX) in Q2 2026: 10 shares worth $550. The stake represents ﹤0.01% of the portfolio and ranks #54 among its holdings.

173 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

Fort Vancouver Investment Management held 10 shares of TG Therapeutics worth $550 as of Q2 2026.
TG Therapeutics was a new Fort Vancouver Investment Management position in Q2 2026.
TG Therapeutics made up ﹤0.01% of Fort Vancouver Investment Management's portfolio in Q2 2026, its #54 holding.
173 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Fort Vancouver Investment Management's 13F filing for Q2 2026, filed 30 Jul 2026.